Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Preliminary Study of the Relationship Between Clozapine-Induced Weight Gain and Menstrual Irregularities in Schizophrenic, Schizoaffective, and Bipolar Women

A Preliminary Study of the Relationship Between Clozapine-Induced Weight Gain and Menstrual... Controversy persists about links between psychotropic drug use, obesity, and consequent menstrual irregularities. Although these interrelationships have been suggested to possibly explain polycystic ovarian syndrome among women taking valproate, less is known about menstrual irregularities associated with weight gain caused by other psychotropics. Clozapine, sparing of prolactin-related menstrual effects yet often associated with weight gain, offers a model psychotropic from which to test such hypotheses. We studied outpatient premenopausal women from a clozapine clinic to preliminarily assess the association between menstrual cycle patterns and body mass index (BMI). Records were reviewed for 13 female premenopausal schizophrenic, bipolar, or schizoaffective outpatients who took clozapine with no conventional antipsychotics for ≥6 months. Mean 6-month menstrual cycle lengths were compared with BMIs and relative weight changes since starting clozapine. Subjects took clozapine (mean ± SD dose 392.2 ± 195.7 mg/day) for a mean ± SD of 4.4 ± 3.2 years, with a mean preclozapine weight increase of 27%. Twenty-three percent had menstrual irregularities in the preceding 6 months (mean ± SD cycle length = 36.4 ± 18.1 days), although no significant associations were observed between cycle length and (a) mean ± SD BMI (32.0 ± 8.4) (r = −0.09, p = 0.78) or (b) weight change since starting clozapine (r = −0.10, p = 0.75). The observed lack of association between clozapine-induced weight gain and menstrual disturbances would provisionally suggest that iatrogenic weight gain does not robustly explain the emergence of irregular menses among premenopausal women taking clozapine. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

A Preliminary Study of the Relationship Between Clozapine-Induced Weight Gain and Menstrual Irregularities in Schizophrenic, Schizoaffective, and Bipolar Women

Download PDF
5 pages

Loading next page...
 
/lp/springer-journals/a-preliminary-study-of-the-relationship-between-clozapine-induced-0loavhqA90
Publisher
Springer Journals
Copyright
Copyright © 2002 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1015267826608
Publisher site
See Article on Publisher Site

Abstract

Controversy persists about links between psychotropic drug use, obesity, and consequent menstrual irregularities. Although these interrelationships have been suggested to possibly explain polycystic ovarian syndrome among women taking valproate, less is known about menstrual irregularities associated with weight gain caused by other psychotropics. Clozapine, sparing of prolactin-related menstrual effects yet often associated with weight gain, offers a model psychotropic from which to test such hypotheses. We studied outpatient premenopausal women from a clozapine clinic to preliminarily assess the association between menstrual cycle patterns and body mass index (BMI). Records were reviewed for 13 female premenopausal schizophrenic, bipolar, or schizoaffective outpatients who took clozapine with no conventional antipsychotics for ≥6 months. Mean 6-month menstrual cycle lengths were compared with BMIs and relative weight changes since starting clozapine. Subjects took clozapine (mean ± SD dose 392.2 ± 195.7 mg/day) for a mean ± SD of 4.4 ± 3.2 years, with a mean preclozapine weight increase of 27%. Twenty-three percent had menstrual irregularities in the preceding 6 months (mean ± SD cycle length = 36.4 ± 18.1 days), although no significant associations were observed between cycle length and (a) mean ± SD BMI (32.0 ± 8.4) (r = −0.09, p = 0.78) or (b) weight change since starting clozapine (r = −0.10, p = 0.75). The observed lack of association between clozapine-induced weight gain and menstrual disturbances would provisionally suggest that iatrogenic weight gain does not robustly explain the emergence of irregular menses among premenopausal women taking clozapine.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Oct 10, 2004

References

  • Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy
    Isojarvi, J; Laatikainen, TJ; Pakarinen, AJ; van Parys, J; Rattya, J; Harbo, HF; Dale, PO; Fauser, BC; Gjerstad, L; Koivunen, R; Knip, M; Tapanainen, JS
  • Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy
    Murialdo, G; Galimberti, CA; Magri, F; Sampaolo, P; Copello, F; Gianelli, MV; Gazzerro, E; Rollero, A; Deagatone, C; Manni, R; Ferrari, E; Polleri, A; Tartara, A
  • Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy
    Murialdo, G; Galimberti, CA; Gianelli, MV; Rollero, A; Polleri, A; Copello, F; Magri, F; Ferrari, E; Sampaolo, P; Manni, R; Tartara, A
  • Polycystic ovary syndrome in patients with focal epilepsy:Astudy in 93 women
    Bauer, J; Jarre, A; Klingmuller, D; Elger, CE
  • Valproate and polycystic ovaries
    Eberle, AJ
  • Effect of obesity on the clinical and hormonal characteristics of the polycystic ovary syndrome
    Singh, KB; Mahajan, DK; Wortsman, J
  • Pathogenesis and treatment of polycystic ovarian syndrome
    McKenna, TJ
  • The relation between obesity and testosteroneestradiol binding globulin levels in PCOS
    Badawy, SZA
  • Medication status and polycystic ovary syndrome in women with bipolar disorder: A preliminary report
    Rasgon, NL; Altshuler, LL; Gudeman, D; Burt, VK; Tanavoli, S; Hendrick, V; Korenman, S
  • Antipsychotic-induced weight gain: A review of the literature
    Allison, DB; Casey, DE
  • Antipsychotic-induced weight gain: A comprehensive research synthesis
    Allison, DB; Mentore, JL; Heo, M; Chandler, LP; Cappelleri, JC; Infante, MC; Weiden, PJ
  • Effect of clozapine on human serum prolactin levels
    Meltzer, HY; Goode, DJ; Schyve, PM; Young, M; Fang, VS
  • Clozapine: Plasma levels and prolactin response
    Kane, JM; Cooper, TB; Sachar, EJ; Halpern, FS; Bailine, S
  • Antipsychotic drugs and reproductive hormones: Relationship to body weight regulation
    Baptista, T; Reyes, D; Hernandez, L
  • Polycystic ovary syndrome
    Franks, S
  • Polycystic ovaries: A common finding in normal women
    Polson, DW; Adams, J; Wadsword, J; Franks, S
  • Epidemiologic correlates with menstrual cycle length in middle aged women
    Kato, I; Toniolo, P; Koenig, KL; Shore, RE; Zeleniuch-Jacquotte, A; Akhmedkhanov, A; Riboli, E
  • Women's reproductive health:The role of body mass index in early and adult life
    Lake, JK; Power, C; Cole, TJ